Ebola virus disease (EVD), a severe, often fatal illness in humans, has remained a major public health concern in many parts of sub-Saharan Africa since it appeared in 1976 in Zaire (now the Democratic Republic of the Congo [DRC]). The severity of disease caused by Ebola virus (family Filoviridae) varies considerably among the 5 known species. Three species (Zaire ebolavirus [ZEBOV], Bundibugyo ebolavirus, and Sudan ebolavirus) have caused outbreaks affecting dozens, and sometimes hundreds, of persons in Africa. Case-fatality rates (CFRs) vary by species and are highest for ZEBOV (up to 90%) (1). The largest EVD epidemic occurred during 2014–2016 in West Africa; it resulted in 28,646 cases and 11,323 deaths and affected 10 countries in Africa, Europe, and North America (2).

Author affiliations: Médecins Sans Frontières, Barcelona, Spain (C. Nanclares, F. Lionetto, O. de la Rosa, M. Alía, A. Bernasconi); Institut National de Recherche Biomédicale, Kinshasha, Democratic Republic of the Congo (J. Kapetshi, J.-J. Muyembe Tamfun); Public Health Agency of Canada, Winnipeg, Manitoba, Canada (G. Kobinger); Swiss Tropical and Public Health Institute, Basel, Switzerland (A. Bernasconi); University of Basel, Basel (A. Bernasconi)

DOI: http://dx.doi.org/10.3201/eid2209.160354

During July–November 2014, the Democratic Republic of the Congo underwent its seventh Ebola virus disease (EVD) outbreak. The etiologic agent was Zaire Ebola virus; 66 cases were reported (overall case-fatality rate 74.2%). Through a retrospective observational study of confirmed EVD in 25 patients admitted to either of 2 Ebola treatment centers, we described clinical features and investigated correlates associated with death. Clinical features were mainly generic. At admission, 76% of patients had ≥1 gastrointestinal symptom and 28% ≥1 hemorrhagic symptom. The case-fatality rate in this group was 48% and was higher for female patients (67%). Cox regression analysis correlated death with initial low cycle threshold, indicating high viral load. Cycle threshold was a robust predictor of death, as were fever, hiccups, diarrhea, dyspnea, dehydration, disorientation, hematemesis, bloody feces during hospitalization, and anorexia in recent medical history. Differences from other outbreaks could suggest guidance for optimizing clinical management and disease control.

Simultaneously, in 2014, another EVD outbreak occurred in Equateur Province in northwestern DRC. The first case, reported on July 26, 2014, in a pregnant woman married to a bush meat hunter, came from the village of Inkanamongo (3,4), close to the town of Boende; she was believed to be the index case-patient. This area is ≈700 km from the capital city, Kinshasa. No paved roads connect the 2 settlements, and communications depend mainly on travelers (3). The World Health Organization (WHO) declared the outbreak on August 24, 2014 (4).

During the outbreak, July 26–October 4, 2014, a total of 66 EVD cases were reported (28 probable, 38 confirmed); 49 deaths were reported, for a CFR of 74%, including deaths in the community of persons with suspected EVD (5,6). One third of these case-patients were documented to have had direct contact with the index case-patient. A basic reproduction number of 0.84 (3) was estimated, which was lower than in any previous EVD epidemic (7). In comparison, West Africa had a reproduction number of 1.7–2.0 for the first 9 months of the outbreak (8). WHO declared the outbreak in DRC over on November 21, 2014, forty-two days after the last EVD case-patient tested negative and was discharged from the hospital (5).

Genome sequencing identified ZEBOV as the outbreak’s causative agent. However, genetic characterization of the virus pointed to a local variant because it has 99.2% of the genome in common with the strain isolated from the 1995 outbreak in Kikwit, DRC, and >96.8% identified in common with the ZEBOV simultaneously circulating in West Africa (3,9).

To respond to this epidemic, in collaboration with the local authorities, Médecins Sans Frontières (MSF) opened an Ebola treatment center (ETC) to manage persons with suspected or confirmed EVD in Lokolia; this ETC was fully functional on September 10, 2014. A second ETC was set up inside the regional hospital in Boende on August 28. The activities in both ETCs were conducted until week 44. We describe the clinical features of EVD and predictors of death among patients treated in these ETCs during the 2014 outbreak in DRC.

Methods
We conducted a retrospective observational study on the basis of medical records of all patients with confirmed
EVD who were admitted for care at the MSF-supported ETCs in Lokolia and Boende during August 28–November 8, 2014. Patients were identified through the standard case definition established by the Ministry of Health in collaboration with WHO (3).

EVD was confirmed by quantitative reverse transcription PCR (RT-PCR), which is considered the most sensitive method and can detect virus from early acute disease through early recovery (10). Initially, samples were sent in dry tubes and EDTA to the Institut National de Recherche Biomédicale (Kinshasa, DRC) to be tested; later the Institut National de Recherche Biomédicale set up a field laboratory in the Lokolia ETC. To confirm EVD, samples were sent to the WHO reference center at the Centre International de Recherche Médicales de Franceville in Gabon (3). Patients were treated in accordance with then-current protocols established for viral hemorrhagic fever by MSF and WHO urgent interim guidance for case management, endorsed by the Ministry of Health of DRC (11,12). Patients with confirmed EVD were discharged after a negative RT-PCR result, 3 days without any major symptoms, and general clinical improvement. For a patient suspected to have EVD, discharge required 2 negative PCR results 48 hours apart, of which 1 was performed at least 72 hours after symptom onset.

**Data Collection**

We collected epidemiologic and demographic data (age, sex), history of exposure, dates of onset, and symptoms and signs before and during hospitalization on an anonymized encrypted electronic database. Each day, as part of their routine clinical duties in the ETCs, health staff recorded the health condition of patients. At discharge, clinicians reviewed the medical files of each patient and double-checked data at the moment of encoding into Microsoft Excel version 2007 (Microsoft Corp., Redmond, WA, USA) before analysis with Stata version 12 (StataCorp LP, College Station, TX, USA). Fever was defined as an axillary body temperature ≥37.5°C (≥99.5°F). We considered hemorrhagic signs as the following: bloody feces; hematemesis; epistaxis; gingival or oral bleeding; nonmenstrual vaginal bleeding; bleeding after an intramuscular injection or venipuncture; and red eyes/subconjunctival hemorrhage, even though conjunctivitis also can cause this sign (3). We grouped as gastrointestinal symptoms the following: nausea, vomiting, diarrhea (bloody and watery diarrhea), and abdominal pain. We measured, in days, the duration of symptoms and signs only for patients who survived. Laboratory data were recorded in a separate register and subsequently were matched with clinical data by using MSF identification. The cycle threshold (Cv) result from the first EVD PCR whole-blood test at admission was used as a proxy indicator of ZEBOV viral load (i.e., the lower the Cv, the higher the viral load) (13). An EVD Cv of 25 is considered equivalent to a viral load of 1.28 × 10⁷ copies/mL of blood (14). Cv s <20 suggest a very high viral load.

**Statistical Analysis**

We restricted our dataset to RT-PCR–positive patients. Results were reported as proportions, means, or medians for the descriptive analysis. We used Fisher exact test to test the hypothesis involving dichotomous variables, Student t test to compare 2 parametric continuous variables, and Mood’s median test to compare nonparametric continuous variables. Variables were modeled in a Probit model to test correlation of continuous (Cv, incubation day, age) or categorical (age group, sex) variables toward the dichotomy outcome (survived/died). Variable normality, when doubtful, was tested with Shapiro-Wilk test to choose the appropriate additional test. The relative risk (RR) and its SE and 95% CI were calculated according to Altman (15). Finally, we tested predictors for death through Kaplan-Meier analysis using the log-rank test of equality for categorical variables and Cox proportional hazard regression for continuous variables to calculate the hazard rate. For survival analysis models, we modeled survival from the day of symptom onset with a censoring time of 30 days because all deaths occurred before 30 days after symptom onset. We included the predictor in the model if the test had a p value ≤0.25. Hypotheses tested were 2-tailed, and we considered statistical significance only in the presence of p values <0.05.

**Results**

Sixty-five persons whose illness met the case definition for EVD were admitted to 1 of the 2 MSF-supported ETCs in Boende and Lokolia during outbreak weeks 35–44. For 25 (38%) patients, EVD was confirmed by RT-PCR. The remaining patients with suspected EVD were determined to have malaria or other infections and were treated accordingly. Of the 25 EVD-confirmed patients, 13 (52%) were male. The 25 EVD patients treated at the ETCs represented 66% of the 38 confirmed EVD cases notified during this outbreak. Twelve (48%) of the 25 case-patients died.

The median age of patients with confirmed EVD was 32 years (range 1–77 years) (Table 1). Male patients were older than female patients (p = 0.03): a median of 32 (25th percentile 12, 75th percentile 47) years versus 25 (25th percentile 6.5, 75th percentile 38.5) years, respectively. Case-patients 15–45 years of age were the most represented (11 [44%]); 9 (36%) case-patients were <15 years of age.

Time from symptom onset to admission, available for 24 patients, averaged 4.69 days (range 1–9 days). This interval was shorter for survivors (4.25 days) than for persons who died (5.21 days) and for female patients (4.82 days) than for male patients (4.61 days). We did not find any
significant difference between the 2 ETCs in terms of delays of hospitalization and outcome. At admission, the most common symptoms reported were asthenia (84%); fever (80%); and anorexia, vomiting, and diarrhea (56% each). In general, gastrointestinal symptoms accounted for 28% of all reported symptoms, but no patients showed signs of dehydration at admission. Hemorrhagic signs, documented at admission for 7 (28%) patients, were mainly gastrointestinal bleedings. Anorexia, myalgia, and abdominal pain occurred significantly more often in adults (patients >15 years of age) than in children (p<0.05). Only anorexia correlated with death (odds ratio [OR] 6.99, p<0.05) (Table 2).

C_{t} at admission was available for 23 (96%) patients. The average C_{t} was 29.2 ± 5.9 (range 17.9–39.1). C_{t} for children <5 years of age was lower, indicating higher viral load, than for children 5–15 years (p<0.01). Two (9%) patients, 1 and 53 years of age, who died had a C_{t} <20. Survivors spent a median of 10 days in the hospital (maximum stay 24 days). The others died a median of 4 days (range 1–18, p = 0.09) after admission.

During hospitalization, asthenia (96%); anorexia and diarrhea (68% each); and vomiting, myalgia, and fever up to 39.5°C (60% each) were the most common symptoms (Table 3). The symptoms of longest duration were asthenia (4 days), red eyes (4 days), tender abdomen (4 days), anorexia (2.9 days), and arthralgia (2.4 days).

In addition to the 7 patients who had hemorrhagic signs at admission, hemorrhagic signs developed in 7 patients during hospitalization. In these patients, bloody feces (7 patients), bleeding from an injection site (6 patients), and red eyes (or subconjunctival hemorrhage) and hematemesis (5 patients) developed. Including red eyes, hemorrhagic signs lasted an average of 3.5 days during hospitalization. Of these 7 patients, 5 died during hospitalization; the 2 survivors had subconjunctival hemorrhage, and 1 had bloody feces. Overall, 14 (56%) patients had hemorrhagic signs during illness. C_{t} at admission was significantly lower for patients with than without hemorrhagic signs (24.83 ± 4.41 vs. 32.59 ± 4.57; p<0.01), and we found no correlation between development of hemorrhage and age or sex.

Nineteen (76%) patients reported at least 1 gastrointestinal symptom before admission. Diarrhea and vomiting were the most common gastrointestinal symptoms (56% each); 10 (40%) patients had both. Ten patients reported abdominal pain. During hospitalization, 2 additional patients had gastrointestinal symptoms, for a total of 21 (84%) patients with at least 1 of these symptoms during illness. Nine (36%) patients also were dehydrated during hospitalization.

Cough was noted for 1 patient, who also had dyspnea, at admission and for 2 patients during their illness. Additionally, at admission, only 1 patient reported dyspnea, and it developed in 5 additional patients during hospitalization (dyspnea developed in 3 patients the day before death). This symptom was suspected to be a preagonic acidosis complication rather than direct respiratory involvement. Moreover, only 1 patient had the characteristic sign of hiccups at admission and it developed in 3 (16%) additional patients during hospitalization. All patients who had hiccups died.

The CFR was the most important outcome analyzed in this study. Of 25 patients hospitalized with confirmed EVD, 12 died, for an overall CFR of 48%. The CFR was higher for female (67%) than for male (31%) patients (Figure 1). The CFR was highest for children <5 years of age (75%)}
followed by persons 15–45 years of age (64%). These age groups also had significantly lower average CI, (<0.01).

The median time from symptom onset to death was 9 days (25th percentile 7, 75th percentile 12, range 3–23 days). Nine (75%) patients who died had at least 1 hemorrhagic sign during illness, and all hemorrhagic signs except red eyes/subconjunctival hemorrhage were associated with higher CFR. All the 12 patients who died had also vomiting, diarrhea, or both at some point during their illness.

Clinical care for the most severely affected patients focused on maintaining circulatory volume and blood pressure, mainly through maintenance of hydration. Nine patients who died received intravenous treatment.

Symptoms such as fever, hiccups, diarrhea, dyspnea, dehydration, disorientation, hematemesis, and bloody feces that developed during hospitalization significantly correlated with an increased risk for death (p<0.01). Lower CI at admission also correlated significantly with death.

A Probit regression model that included CI at admission and sex indicated that an increase in CI, correlated with a decreased probability of death by –0.038 (95% CI –0.059 to –0.018; p<0.01) (Figure 2). A Cox regression model that included CI, at admission, age, and sex confirmed that CI, was the best predictor of death (hazard ratio 0.81, 95% CI 0.68–0.96; p = 0.02 (Cox, Table 4).

Discussion
In 2014, in parallel with the large EVD outbreak in West Africa, the DRC faced its seventh outbreak of EVD since the first report of the virus in 1976 (Table 5). By the end of this lesser-known outbreak, 49 persons with EVD had died, for a CFR of 74% (3), a rate consistent with previous EVD outbreaks in the region (16) but higher than with the EVD outbreak caused by Bundibugyo virus in Isiro, DRC, in 2012 (CFR 46.7%) (17,18) and in Kasai Oriental province, DRC, in 2008 (43.7%) (19). Although this rate could be overestimated because of a lack of information about possible survivors in the community, most EVD patients died during the first phase of the outbreak, before the implementation of an adequate referral and treatment system. Following the model established in 1995 (20), care for a large number of patients occurred in hospital and the MSF-supported ETCs in Lokolia and Boende. However, during epidemiologic weeks 36–44, the CFR of 48% for the 25 persons with confirmed EVD treated in the 2 ETCs did not differ substantially from the 43% reported by Bah et al. in Conakry, Guinea (21), and from the 51% reported by Fitzpatrick et al. in Sierra Leone (14).
Table 3. Symptoms and signs developed during hospitalization during the Ebola virus disease outbreak in Ebola treatment centers, Lokolia and Boende, Democratic Republic of the Congo, July–November 2014*

| Symptom, sign                        | Survived, no. (%) | Died, no. (%) | Total, no. (%) | Average no. days | CFR | Relative risk (95% CI) | p value |
|--------------------------------------|-------------------|---------------|----------------|------------------|-----|------------------------|---------|
| Symptom                              |                   |               |                |                  |     |                        |         |
| Asthenia                             | 12 (92.3)         | 12 (100)      | 24 (96.0)      | 4                | 50.0| 0                      | 0.0003  |
| Anorexia                             | 7 (53.8)          | 10 (83.3)     | 17 (68.0)      | 2.9              | 58.8| 2.35 (0.66–8.33)       | 0.2     |
| Myalgia                              | 6 (46.1)          | 9 (75.0)      | 15 (60.0)      | 2.3              | 60.0| 2 (0.71–5.62)          | 0.22    |
| Arthralgia                           | 5 (38.4)          | 6 (50.0)      | 11 (44.0)      | 2.4              | 54.5| 1.27 (0.56–2.86)       | 0.69    |
| Headache                             | 6 (46.1)          | 5 (41.7)      | 11 (44.0)      | 2                | 45.5| 0.90 (0.39–2.09)       | 0.1     |
| RUQ abdominal pain                   | 3 (23.1)          | 7 (58.3)      | 10 (40.0)      | 2.3              | 70.0| 2.10 (0.92–4.78)       | 0.11    |
| Difficulty swallowing                | 2 (15.4)          | 6 (50.0)      | 8 (32.0)       | 1                | 75.0| 2.12 (0.99–4.53)       | 0.09    |
| Nausea                               | 3 (23.1)          | 5 (41.7)      | 8 (32.0)       | 2.3              | 62.5| 1.52 (0.69–3.31)       | 0.41    |
| Dyspnea                              | 0 (0)             | 6 (50.0)      | 6 (24.0)       | 100.0            | 3.16| (1.63–6.13)            | 0.005   |
| Disorientation                       | 0 (0)             | 6 (50.0)      | 6 (24.0)       | 100.0            | 3.16| (1.63–6.14)            | 0.005   |
| Cough                                | 1 (7.7)           | 2 (16.6)      | 3 (12.0)       | 12               | 66.7| 1.46 (0.58–3.69)       | 0.09    |
| Chest pain                           | 1 (7.7)           | 2 (16.6)      | 3 (12.0)       | 12               | 66.7| 1.46 (0.58–3.69)       | 0.09    |
| Back pain                            | 1 (7.7)           | 8 (32.0)      | 9 (36.0)       | 1                | 50.0| 1.04 (0.24–4.45)       | 10      |
| Stomach pain/cramps                  | 2 (15.4)          | 0             | 2 (8.0)        | 1                | 0   | 0                      | 0       |
| Diarrhea                             | 6 (46.1)          | 11 (91.7)     | 17 (68.0)      | 2.3              | 64.7| 5.17 (0.8–33.5)        | 0.03    |
| Fever up to 39.5°C                   | 4 (33.3)          | 11 (91.7)     | 15 (60.0)      | 1.5              | 73.3| 7.33 (11.9–48.2)       | 0.003   |
| Vomiting                             | 7 (53.8)          | 8 (66.7)      | 15 (60.0)      | 1.3              | 53.3| 1.33 (0.54–3.20)       | 0.68    |
| Dehydration                          | 1 (7.7)           | 8 (66.7)      | 9 (36.0)       | 1                | 88.9| 3.55 (1.47–8.56)       | 0.003   |
| Hiccups                              | 0 (0)             | 4 (33.3)      | 4 (16.0)       | 100.0            | 2.62| (1.52–4.53)            | 0.04    |
| Tender abdomen                       | 1 (7.7)           | 2 (16.6)      | 3 (12.0)       | 4                | 66.7| 1.46 (0.58–3.68)       | 0.09    |
| Fever >39.5°C                        | 1 (7.7)           | 1 (4.0)       | 2 (8.0)        | 1                | 50.0| 1.04 (0.24–4.45)       | 10      |
| Nonhemorrhagic rash                  | 0 (0)             | 1 (8.3)       | 1 (4.0)        | 100.0            | 2.18| (1.41–3.37)            | 0.48    |

Hemorrhagic sign

| Hemorrhagic                          | 4 (30.7)          | 9 (75.0)      | 13 (52.0)      | 3.5              | 69.20| 2.77 (0.97–7.87)       | 0.04    |
| Hemorrhagic, excluding red eyes/subconjunctival hemorrhage | 2 (15.4) | 9 (75.0) | 11 (44.0) | 1 | 85.70 | 3.81 (1.34–10.8) | 0.03 |

Bloody feces

| Bleeding from injection site         | 1 (7.7)           | 6 (50.0)      | 7 (28.0)       | 1                | 85.7| 2.57 (1.25–5.28)       | 0.03    |
| Red eyes/subconjunctival hemorrhage  | 3 (23.1)          | 3 (25.0)      | 6 (24.0)       | 4                | 50.0| 1.05 (0.41–2.67)       | 0.1     |

Hematemesis

| Hemoptysis                           | 0                  | 5 (41.7)      | 5 (20.0)       | 100.0            | 2.87| (1.57–5.19)            | 0.01    |
| Epistaxis                            | 0                  | 2 (16.6)      | 2 (8.0)        | 100.0            | 2.30| (1.44–3.66)            | 0.22    |
| Gingival/oral bleeding               | 0                  | 1 (8.3)       | 1 (4.0)        | 100.0            | 2.18| (1.41–3.37)            | 0.48    |

*RUQ, right upper quadrant.

Although possibly biased by the case definition, asthenia (84%) and fever (80%) were the most common symptoms at admission, followed by diarrhea, anorexia, and vomiting (56% each). Among these, only anorexia correlated with death (p = 0.01). Gastrointestinal symptoms (mainly vomiting and diarrhea) were common at presentation, which numerous other groups also have reported (8,16,17,21–25). Among all patients in the cohort reported here, at admission at least 7.6 of every 10 patients had 1 gastrointestinal symptom or difficulty swallowing and 4 patients had diarrhea and vomiting, posing an increased risk for transmission, as was documented in West Africa (8,24,25). In contrast, no cholera-like diarrhea symptoms were observed in this outbreak, in contrast to several locations in West Africa during the 2014–2016 outbreak (26), and the DRC patients admitted to the MSF ETCs had no clinically relevant sign of dehydration. The high prevalence of gastrointestinal symptoms we noted indicates that these symptoms should not be ignored during EVD screening and as part of transmission control efforts. Failing to recognize gastrointestinal symptoms early during the course of disease increases the potential for fatal misdiagnosis (16,24,27,28) and for delayed declaration of the outbreak (20,27,29).

Although the ZEBOV isolated during this outbreak is 99% homologous to the Kikwit strain from 1995 (3), the high frequency of maculopapular rash, bilateral conjunctival injection, and sore throat with odynophagia reported in many of the patients from the 1995 outbreak were not observed in this outbreak (16,30). Also, high frequencies of coughing and hemoptysis, which were common in the 1995 outbreak, were not observed. We did not find a high prevalence of other symptoms, such as difficulty swallowing, arthralgia, and nausea, among the patients in our study, as was described in Isiro (17,23) and in Kikwit (16). Hiccups, considered a characteristic and severe sign of EVD...
(31), occurred in only 1 patient at admission without the co-presence of any hemorrhagic sign, and hiccups developed in 3 (16%) additional patients during hospitalization, similar to what was described in Kikwit (16).

Guimard et al. reported that conjunctivitis was highly predictive of EVD and included it in an algorithm for EVD diagnosis (20) because it has been described as a relatively early sign of EVD, detectable in 45%–60% of patients (30). At Connaught Hospital (Freetown, Sierra Leone), conjunctivitis was much more prevalent in the early phase of the outbreak in 2014 than in the latter stages (25). In our study, the documented sign of red eyes/subconjunctival hemorrhage is mainly attributable to conjunctivitis, and its presence did not increase the risk for death (RR 1.05). By calculating the risk for death in correlation with at least 1 hemorrhagic sign, if we included red eyes/subconjunctival hemorrhage as a hemorrhagic sign, we assessed an RR of 3.81. However, if we excluded conjunctivitis, the RR is 2.77. Although conjunctivitis was considered a risk factor in the early phase of the EVD outbreak in West Africa (8) and can be common in EVD patients, our findings suggest its value should be reconsidered.

The prevalence of hemorrhagic signs (52%) among the patients treated during the 2014 outbreak in the DRC did not differ from that described in Uganda (Bundibugyo virus) (18,23) but was higher than the 41% observed in Kikwit and lower than the 78% in the first EVD outbreak in Zaire in 1976 (16,32). Recent reports documenting the West Africa epidemic reported lower prevalence: 0.9% (24); <1% to 5.7% (8); <5% (26); 6%, reporting in this case only melena and hematemesis (25); and 1.9% (22). Only Bah et al. (21) reported 51% of EVD patients with hemorrhages, but in this case also subconjunctival redness, which might have been conjunctivitis, was included.

We did not observe a significant correlation between older age and death (p = 0.16) in a Probit model with C at admission and sex, as described previously (8,18,21,24,33). Female sex was the main risk factor associated with death (RR 2.16, p = 0.07), but once adjusted for C and age in a Cox regression model, it was no longer significantly associated with death (hazard rate 4.47, p = 0.22). Other groups have reported that male patients were more at risk than female patients for death in the context of EVD (33).

Overall, C at admission was the only statistically significant predictor of death (p<0.01). Average C at admission also was lower for case-patients who died than for those who survived (9.5 vs. 11.5, p<0.01). This association between high viral load and death was reported recently (10) in West Africa (14,24) and in Uganda in 2000 (29). In our study, low C also was associated with severe hemorrhagic signs during hospitalization.

We report a clinical dataset for the seventh EVD outbreak in the DRC. Although it comprises all the patients admitted in 2 ETCs, the relatively small number of
cases documented is a limitation of the study and should be considered in drawing conclusions from these data. Consequently, some level of selection bias cannot be excluded because some persons with minor symptoms or very serious EVD are likely not to have arrived at an ETC. Nevertheless, our analysis provides a better understanding of symptoms and viral loads in relation to clinical outcome.

Acknowledgments
We are grateful to all the staff in the field who cared for the patients during their hospitalization, working tirelessly under extremely harsh conditions, and to Rob Kozak for editing the article.

Dr. Nanclares is an internal medicine specialist and technical advisor for internal medicine and viral hemorrhagic fever in the medical department in Médecins Sans Frontières Operational Cell Barcelona. Her research interests include infectious and chronic diseases.

References
1. World Health Organization. Ebola virus disease fact sheet [cited 2015 Oct 15]. http://www.who.int/mediacentre/factsheets/fs103/en
2. World Health Organization. Ebola situation report—27 March 2016 [cited 2016 Apr 23]. http://www.who.int/csr/disease/ebola/situation-reports/en
3. Maganga GD, Kapetshi J, Berthet N, Kebela Ilunga B, Kabange F, Mbala Kingebebi P, et al. Ebola virus disease in the Democratic Republic of Congo. N Engl J Med. 2014;371:2083–91. http://dx.doi.org/10.1056/NEJMoa1411099
4. World Health Organization. Ebola virus disease—Democratic Republic of Congo [cited 2015 Oct 15]. http://www.afro.who.int/en/clusters-a-programmes/epidemic-a-pandemic-alert-and-response/outbreak-news/4263-ebola-virus-disease-drc.html
5. Centers for Disease Control and Prevention. 2014 Ebola outbreak in Democratic Republic of the Congo [cited 2015 Oct 15]. http://www.cdc.gov/vhf/ebola/outbreaks/drc/2014-august.html
6. Ministre de la Santé. Déclaration de la fin de l’épidémie d’Ebola en République Democratique du Congo [cited 2015 Oct 15]. http://www.minsanterdc.cd/new/index.php/directon/145-declaration-de-la-fin-de-l-epidemie-d-ebola-en-re-publie-democratique-du-congo
7. Barbarossa MV, Dènes A, Kiss G, Nakata Y, Röst G, Vizi Z. Transmission dynamics and final epidemic size of Ebola virus disease outbreaks with varying interventions. PLoS One. 2015;10:e0131398. http://dx.doi.org/10.1371/journal.pone.0131398
8. WHO Ebola Response Team. Ebola virus disease in West Africa— the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371:1481–95. http://dx.doi.org/10.1056/NEJMoa1411100
9. Alexander KA, Sanderson CE, Marathe M, Lewis BL, Rivers CM, Shuman J, et al. What factors might have led to the emergence of Ebola in West Africa? PLoS Negl Trop Dis. 2015;9:e0003652. http://dx.doi.org/10.1371/journal.pntd.0003652
10. Towner JS, Rollin PE, Bausch DG, Sanchez A, Cray SM, Vincent M, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol. 2004;78:4330–41. http://dx.doi.org/10.1128/JVI.78.4.4330-4341.2004
11. Sterk E. Filovirus haemorrhagic fever guideline [cited 2015 Oct 15]. https://www.medbox.org/filovirus-haemorrhagic-fever-guide-line/download.pdf
12. World Health Organization. Clinical management of patients with viral haemorrhagic fever. A pocket guide for the front-line health worker. Interim emergency guidance—generic draft for West African adaptation. Geneva: The Organization: 2014.
13. Spengler JR, McElroy AK, Harmon JR, Ströhler U, Nichol ST, Spiropoulou CF. Relationship between Ebola virus real-time quantitative polymerase chain reaction–based threshold cycle value and virus isolation from human plasma. J Infect Dis. 2015;212(Suppl 2):S346–9. http://dx.doi.org/10.1093/infdis/jiv187
14. Fitzpatrick G, Vogt F, Moi Gbabai OB, Decroo T, Keane M, De Clerck H, et al. The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Médecins Sans Frontières Ebola case management centre, Kailahun, Sierra Leone, June–October 2014. J Infect Dis. 2015;212:1752–8. http://dx.doi.org/10.1093/infdis/jiv304
15. Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991.
16. Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis. 1999;179(Suppl 1):S1–7. http://dx.doi.org/10.1086/514308
17. Kratz T, Roddy P, Tshomba Oloma A, Jeffs B, Pou Cinuelo D, de la Rosa O, et al. Ebola virus disease outbreak in Isiro, Democratic Republic of the Congo, 2010;16:1969–72. http://dx.doi.org/10.3201/eid1612.100627
18. Reed Z, et al. Proportion of deaths and clinical features in 103 patients. J Infect Dis. 1999;179(Suppl 1):S268–73. http://dx.doi.org/10.1086/514315
19. Towner JS, Rollin PE, Bausch DG, Sanchez A, Cray SM, Vincent M, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol. 2004;78:4330–41. http://dx.doi.org/10.1128/JVI.78.4.4330-4341.2004
21. Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med. 2015;372:40–7. http://dx.doi.org/10.1056/NEJMoa1411249
22. Yan T, Mu J, Qin E, Wang Y, Liu L, Wu D, et al. Clinical characteristics of 154 patients suspected of having Ebola virus disease in the Ebola holding center of Jui Government Hospital in Sierra Leone during the 2014 Ebola outbreak. Eur J Clin Microbiol Infect Dis. 2015;34:2089–95. http://dx.doi.org/10.1007/s10096-015-2457-z
23. MacNeil A, Farnon EC, Wamala J, Okware S, Cannon DL, Reed Z, et al. Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emerg Infect Dis. 2010;16:1969–72. http://dx.doi.org/10.3201/eid1612.100627
24. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, et al.; KGH Lassa Fever Program; Viral Hemorrhagic Fever Consortium; WHO Clinical Response Team. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371:2092–100. http://dx.doi.org/10.1056/NEJMoa1411680
25. Lado M, Walker NF, Baker P, Haroon S, Brown CS, Youkeec D, et al. Clinical features of patients isolated for suspected Ebola virus disease at Connaught Hospital, Freetown, Sierra Leone: a retrospective cohort study. Lancet Infect Dis. 2015;15:1024–33. http://dx.doi.org/10.1016/S1473-3099(15)00137-1
26. Chertow DS, Kleine C, Edwards JK, Scaini B, Giuliani R, Sprecher A. Ebola virus disease in West Africa—clinical manifestations and management. N Engl J Med. 2014;371:2054–7. http://dx.doi.org/10.1056/NEJMp1413084
27. Heymann DL, Barakamfityi D, Szczeniowski M, Muyembe-Tamfum JJ, Bele O, Rodier G. Ebola hemorrhagic fever: lessons from Kikwit, Democratic Republic of the Congo. J Infect Dis. 1999;179(Suppl 1):S283–6. http://dx.doi.org/10.1086/514287
28. Bonnet MJ, Akamituna P, Mazaya A. Unrecognized Ebola hemorrhagic fever at Mosango Hospital during the 1995 epidemic in Kikwit, Democratic Republic of the Congo. Emerg Infect Dis. 1998;4:508–10. http://dx.doi.org/10.3201/eid0403.980349
29. Muyembe-Tamfum JJ, Kipasa M, Kiyungu C, Colebunders R. Ebola outbreak in Kikwit, Democratic Republic of the Congo: discovery and control measures. J Infect Dis. 1999;179(Suppl 1):S259–62. http://dx.doi.org/10.1086/514302
30. Kibadi K, Mupapa K, Kuvula K, Massamba M, Ndaberey D, Muyembe-Tamfum JJ, et al. Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J Infect Dis. 1999;179(Suppl 1):S13–4. http://dx.doi.org/10.1086/514288
31. Sureau PH. Firsthand clinical observations of hemorrhagic manifestations in Ebola hemorrhagic fever in Zaire. Rev Infect Dis. 1989;11(Suppl 4):S790–3. http://dx.doi.org/10.1093/clinids/11. World Health Organization. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56:271–93.
32. Sadek RF, Khan AS, Stevens G, Peters CJ, Ksiazek TG. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J Infect Dis. 1999;179(Suppl 1):S24–7. http://dx.doi.org/10.1086/514311

Address for correspondence: Andrea Bernasconi, Schafmattweg 67d, 4201 Binningen, Switzerland; email: doigb2@yahoo.it

February 2016: Ebola

Including:

• Ebola Virus Persistence in Semen Ex Vivo
• Epidemiology of Epidemic Ebola Virus Disease in Conakry and Surrounding Prefectures, Guinea, 2014–2015
• Hospital Preparations for Viral Hemorrhagic Fever Patients and Experience Gained from the Admission of an Ebola Patient
• Prognostic Indicators for Ebola Patient Survival
• Initial Costs Incurred by Ebola Treatment Centers, United States
• AP92-like Crimean-Congo Hemorrhagic Fever Virus in Hyalomma aegyptium ticks, Algeria
• Ebola Virus RNA Stability in Human Blood and Urine in West Africa’s Environmental Conditions
• Feasibility of Xpert Ebola Assay in Médecins Sans Frontières Ebola Program, Guinea
• Uveitis and Systemic Inflammatory Markers in Convalescent Phase of Ebola Virus Disease
• Molecular Characterization of Invasive Streptococcus dysgalactiae subsp. equisimilis, Japan
• Hemorrhagic Fever with Renal Syndrome, Zibo City, China, 2006–2014
• Ebola and Its Control in Liberia, 2014–2015

http://wwwnc.cdc.gov/eid/articles/issue/22/02/table-of-contents